gene therapy stock shows promise amid risks By Investing.com
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage biotechnology company with a market capitalization of $348 million specializing in gene therapies for neurological disorders, has recently garnered attention from Wall Street analysts. The company’s lead asset, NGN-401, a gene therapy for Rett syndrome, has shown promising results in early-stage clinical trials, positioning Neurogene as a potential leader in this therapeutic area. InvestingPro data shows the stock has delivered an impressive 54% return over the past year, despite recent market volatility.
Company Overview
Neurogene focuses on developing advanced gene therapies for neurological disorders. The company’s primary focus is on Rett syndrome, a rare genetic neurological disorder…
